Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Enantioselectivity Effects in Clinical Metabolomics and Lipidomics

Full text
Oliveira, Regina V. [1] ; Simionato, Ana Valeria C. [2, 3] ; Cass, Quezia B. [1]
Total Authors: 3
[1] Univ Fed Sao Carlos, Dept Chem, SEPARARE Nucleo Pesquisa Cromatog, Rod Washington Luiz, Km 235, BR-13565905 Sao Carlos, SP - Brazil
[2] Univ Estadual Campinas, Inst Chem, Dept Analyt Chem, BR-13083970 Campinas, SP - Brazil
[3] Univ Estadual Campinas, Natl Inst Sci & Technol Bioanalyt, Inst Chem, BR-13083970 Campinas, SP - Brazil
Total Affiliations: 3
Document type: Review article
Source: Molecules; v. 26, n. 17 SEP 2021.
Web of Science Citations: 0

Metabolomics and lipidomics have demonstrated increasing importance in underlying biochemical mechanisms involved in the pathogenesis of diseases to identify novel drug targets and/or biomarkers for establishing therapeutic approaches for human health. Particularly, bioactive metabolites and lipids have biological activity and have been implicated in various biological processes in physiological conditions. Thus, comprehensive metabolites, and lipids profiling are required to obtain further advances in understanding pathophysiological changes that occur in cells and tissues. Chirality is one of the most important phenomena in living organisms and has attracted long-term interest in medical and natural science. Enantioselective separation plays a pivotal role in understanding the distribution and physiological function of a diversity of chiral bioactive molecules. In this context, it has been the goal of method development for targeted and untargeted metabolomics and lipidomic assays. Herein we will highlight the benefits and challenges involved in these stereoselective analyses for clinical samples. (AU)

FAPESP's process: 20/05965-8 - Metabolomic strategies based on LC-HRMS for investigation of potential biomarkers for clinical diagnosis - Phase I
Grantee:Regina Vincenzi Oliveira
Support Opportunities: Regular Research Grants